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Potential effect of age of BCG vaccination on global 
paediatric tuberculosis mortality: a modelling study
Partho Roy, Johan Vekemans, Andrew Clark, Colin Sanderson, Rebecca C Harris*, Richard G White*
Summary
Background BCG has been recommended at birth in countries with a high tuberculosis burden for decades, yet 
delayed vaccination is widespread. To support a WHO guidance review, we estimated the potential global tuberculosis 
mortality benefit of administering BCG on time and consequences of later administration.
Methods We estimated age-specific BCG coverage in 152 high-burden countries using data from large, nationally 
representative household surveys, to parameterise a static mathematical model, calibrated to global childhood 
tuberculosis deaths in 2016. 12 hypothetical scenarios explored the effect of BCG delivery at birth, 6 weeks, 6 months, 
or 9–12 months, on tuberculosis deaths per global birth cohort by age 15 years, including delivery at the time of the 
first diphtheria–tetanus–pertussis vaccine (DTP1) or the first measles-containing vaccine (MCV1). We assumed 
constant vaccine efficacy by age, but varied coverage and degree of vaccination delay, including no delay.
Findings In 152 high-burden countries, we estimated that BCG coverage in 2016 was 37% at 1 week of age, 67% at 
6 weeks, and 92% at 3 years. Modelled scenarios in which 92% BCG coverage was achieved at birth reduced 
tuberculosis deaths in the global birth cohort by 5449 (95% uncertainty range 218–15 071) or 2·8% (0·1–7·0) by age 
15 years. 100% coverage at birth reduced tuberculosis deaths by 16·5% (0·7–41·9). Later administration increased 
tuberculosis deaths—eg, BCG vaccination at 6 weeks, the recommended age of DTP1, increased tuberculosis deaths 
by 0·2% (0–0·4), even if BCG reached DTP1 coverage levels (94% at 3 years).
Interpretation Reducing delays and increasing coverage at birth would substantially reduce global paediatric 
tuberculosis mortality. Modelled scenarios whereby BCG was administered later in the infant schedule were all 
estimated to increase tuberculosis deaths, even with increased coverage. The WHO recommendation for BCG at birth 
should be maintained and emphasised.
Funding WHO.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
BCG vaccine was introduced into WHO’s Expanded 
Programme on Immunization in 1974 and it remains the 
only tuberculosis vaccine on the market today. It is given 
to approximately 100 million children worldwide each 
year.1
BCG prevents the most severe forms of childhood 
tuberculosis, reducing the risk of meningeal and miliary 
tuberculosis by 85% (95% CI 69–92),2 and tuberculosis-
associated death by 66% (8–88).3 At between US$2–3 
per dose, it is a highly cost-effective intervention, esti-
mated to prevent one case of tuberculosis meningitis in 
the first 5 years of life for every 3435 vaccinations given, 
and one case of miliary tuberculosis for every 9314 vac-
cina tions given.1 Modelling suggests that global BCG 
shortfalls that occurred in 2015 might lead to an 
additional 7433 tuberculosis deaths in the affected birth 
cohort in the first 15 years of life.4 Emerging evidence is 
also suggestive of BCG providing non-specific beneficial 
effects on all-cause mortality.5
BCG has been recommended at birth in countries with 
a high tuberculosis burden for decades. Currently, 
152 low-income and middle-income countries (LMICs) 
have a policy of universal neonatal vaccination at birth or 
in the first week of life.6 Even so, childhood vaccinations, 
including BCG, are often delayed until well after the 
recommended age.7 In support of a WHO guidance 
review and to inform an update to its BCG position 
paper,8 we investigated the potential global tuberculosis 
mortality benefit of administering BCG on time and 
modelled the consequences of BCG administered later in 
the infant schedule.
Methods
Mathematical model
A static mathematical model was developed using 
Microsoft Excel 2016 (Microsoft Corporation, Redmond, 
WA, USA) to calculate the change in number of 
tuberculosis deaths per birth cohort in the first 15 years 
of life (∆pTBD), in each scenario of different age at 
BCG vaccination, compared with the baseline scenario 
(scenario A: BCG vaccination coverage by age distribution 
for the 2016 birth cohort [92% final coverage]):
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∆pTBD= (equation 1)
pTBDscenario
pTBDbaseline
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The number of paediatric tuberculosis deaths per birth 
cohort in the first 15 years of life (pTBD) for the baseline 
and each scenario was estimated by:
Where t represents age (weeks), nt the number of 
unprotected children at age t, and R0–4 and R5–14 were 
the weekly individual risk of tuberculosis death in 
unprotected children aged 0–4 years or 5–14 years, 
respectively (as calculated in equation 7).
In each scenario, nt was estimated to be the number 
of unvaccinated children at age t plus the number of 
children vaccinated but with insufficient immune res-
ponse to prevent tuberculosis death at age t:
where Ut is the number of unvaccinated children at age t, 
Vt the number of vaccinated children at age t, and VE 
vaccine efficacy (proportion), calculated as:
where BC is the global annual number of BCG eligible 
births, Dt the global number of all-cause deaths in BC at 
age t, Covt the proportion of BC vaccinated at age t, and 
RR the rate ratio of tuberculosis deaths in BCG vaccinated 
versus unvaccinated neonates.
In the baseline scenario (scenario A; table 1, figure), 
the model was calibrated to the 2016 WHO estimate of 
paediatric tuberculosis deaths. In this baseline scenario, 
the WHO estimate of paediatric tuberculosis deaths 
was randomly sampled 100 000 times, and used in 
conjunction with estimates of age-specific BCG vaccine 
coverage data, the sampled proportion of tuberculosis 
deaths estimated to occur in children aged 0–4 years and 
5–14 years, and other sampled parameters (table 2), to 
inform the value of the age-specific weekly individual 
risk of tuberculosis death in unprotected children aged 
0–4 years and 5–14 years for each sampled parameter set:
where a is the age group (0–4 years or 5–14 years), Morta 
the number of tuberculosis deaths in each age group, 
and ∑na the number of unprotected person-weeks in each 
age group.
The calculated age-specific risk of tuberculosis death in 
unprotected children (Ra) from the baseline scenario was 
Research in context
Evidence before this study
WHO estimated that approximately 253 000 children younger 
than 15 years died from tuberculosis in 2016, including 
52 000 deaths in children with HIV. Modelling estimates 
suggest that the majority of childhood tuberculosis deaths 
occurred in children younger than 5 years, although the 
number of these deaths occurring in children younger than 
2 years—who are at greatest risk of tuberculosis death—is not 
known. BCG vaccine has been recommended at birth in high 
tuberculosis burden countries for decades. However, delays in 
vaccination are widespread and many vaccines, including BCG, 
are delivered after the recommended age. Meta-analyses have 
shown that neonatal BCG vaccination provides protection 
against meningeal tuberculosis, miliary tuberculosis, and 
against tuberculosis death. Evidence on whether BCG vaccine 
efficacy varies by age of administration is extremely scarce. 
To explore the existing literature on the population-level effect 
of changes in timing of BCG vaccination on childhood 
mortality, we searched MEDLINE, Embase, and PubMed for all 
English language studies published between database 
inception and June 30, 2016, using MeSH search terms for 
BCG, children, tuberculosis, and timing. One study estimated 
the population-level effect of BCG on morbidity, but no studies 
were identified exploring the population-level effects of 
changes in the timing of BCG vaccination on tuberculosis 
mortality.
Added value of this study
This study is the first to explore the potential effect of age of 
BCG vaccination on global paediatric tuberculosis mortality. 
This study provides evidence of the benefits of administering 
BCG vaccination at birth, and the potential reduction in global 
tuberculosis deaths that could be achieved with on-time 
vaccination. Prospective evaluation of the effect of age of BCG 
on tuberculosis mortality would be challenging for many 
reasons and mathematical modelling studies such as this study 
can provide valuable information, alongside available data, to 
support vaccine recommendations. 
Implications of all the available evidence
The recommendation for the birth dose of BCG should be 
maintained and emphasised. This recommendation is 
supported by previous literature showing high protection 
against pulmonary, miliary, and meningeal tuberculosis if given 
to neonates, and by our evaluation showing that current delays 
in BCG vaccination are associated with increased global 
paediatric tuberculosis mortality. Through eliminating these 
delays and increasing BCG coverage at birth, substantial 
reductions in global paediatric tuberculosis mortality could be 
achieved. Our analysis supports the updated WHO position 
paper on BCG vaccines.
nt=Ut + (Vt × [1 − VE]) (equation 3)
Ut =([BC − Dt] × [1 − Covt]) (equation 4)
Vt=(BC − Dt) × Covt (equation 5)
VE=1 − RR (equation 6)
pTBD= (equation 2)∑t=261 nt × R0–4t=0( )+ ∑
t=782 nt × R5–14t=262( )
Ra=
Morta
Σna
(equation 7)
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used to estimate the change in number of tuberculosis 
deaths per birth cohort in the first 15 years of life for each 
vaccination scenario.
Data and model assumptions
Data inputs, model assumptions, and sources are sum-
marised in table 2. The global number of BCG eligible 
births was estimated at 129·1 million, calculated from the 
annual number of births from 152 LMICs with a policy of 
universal neonatal vaccination6 using UN Population 
Division (UNPD) birth estimates (2017 revision).9 The 
birth cohort was not adjusted for children born with HIV 
for whom BCG might be contraindicated, because data 
on this parameter are limited and likely to be small (with 
a maximum potential adjustment of <0·2% of birth 
cohort).10 The weekly number of childhood all-cause deaths 
Age of BCG delivery Scenario description
A Birth Baseline scenario, BCG vaccination coverage by age distribution for the 2016 birth cohort
B Birth 92% immediate coverage at birth
C Birth 100% immediate coverage at birth
D 6 weeks 0% coverage until 6 weeks of age, then 92% immediate coverage at 6 weeks
E 6 weeks 0% coverage until 6 weeks of age, then 92% final coverage delaying the baseline BCG coverage distribution by 6 weeks
F1 6 weeks BCG global delivery at the time of DTP1, using DTP1 coverage by age distribution (capped when coverage reached 92%)
F2 6 weeks BCG global delivery at the time of DTP1, using DTP1 coverage by age distribution (final coverage of 94%)
G 6 months 0% coverage until 6 months of age, then 92% immediate coverage at 6 months
H 6 months 0% coverage until 6 months of age, then 92% final coverage delaying the baseline BCG coverage distribution by 6 months
I1 9 or 12 months BCG global delivery at the time of MCV1, using MCV1 coverage by age distribution (capped when coverage reached 92%)
I2 9 or 12 months BCG global delivery at the time of MCV1, using MCV1 coverage by age distribution (final coverage of 93%)
J 12 months 0% coverage until 12 months of age, then 92% immediate coverage at 12 months
K 12 months 0% coverage until 12 months of age, then 92% final coverage delaying baseline BCG coverage distribution by 12 months
Scenario A (baseline scenario) is the BCG vaccination coverage by age distribution for the 2016 birth cohort. Scenarios B–K are hypothetical BCG vaccination scenarios with 
vaccine delivery from birth to 12 months of age. DTP1=first diphtheria–tetanus–pertussis vaccine dose. MCV1=first measles-containing vaccine dose.
Table 1: BCG vaccination scenarios
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Figure: BCG vaccination scenarios
Scenario A (baseline scenario) is the BCG vaccination coverage by age distribution for the 2016 birth cohort. Scenarios B–K are hypothetical BCG vaccination scenarios 
with vaccine delivery from birth to 12 months of age. 
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in the birth cohort was estimated using UNPD mortality 
estimates for children aged 0–4 years, 5–9 years, and 
10–14 years, assuming all-cause deaths were distributed 
equally by week within each of these age categories.11
WHO estimates of the number of global paediatric 
tuberculosis deaths are summarised in table 2. Given that 
more than 90% of paediatric HIV infections have been 
attributed to mother-to-child-transmission,12 and that 
BCG is contraindicated in HIV-infected children unless 
immu nologically stable and on antiretroviral therapy,8 we 
assumed that HIV-positive tuberculosis deaths were not 
preventable through BCG vaccination. Therefore, only 
HIV-negative tuberculosis deaths, constituting 80% of all 
tuberculosis deaths among children aged 0–14 years,13 
were included in the model.
As per previous modelling studies,4 the annual global 
tuberculosis mortality in children aged 0–14 years was 
assumed to be equivalent to the tuberculosis mortality of 
a single global birth cohort over the first 15 years of life. 
The number of tuberculosis deaths that occurred in the 
birth cohort between ages 0–4 years and 5–14 years was 
calculated by applying the proportion of tuberculosis 
deaths that was estimated to occur in these two age 
groups in research by Dodd and colleagues14 to the 2016 
WHO tuberculosis mortality estimate of children aged 
0–14 years.13
To account for realistic timing of vaccination, we 
estimated the 2016 country-specific coverage by age of 
BCG, the first dose of diphtheria–tetanus–pertussis 
vaccine (DTP1), and the first dose of measles-containing 
vaccine (MCV1) for 152 LMICs with a policy of universal 
neonatal BCG vaccination using data from large nation-
ally representative household surveys and previously 
described methods.7 Data from 47 US Agency for 
International Development Demographic and Health 
Surveys and 42 UNICEF Multiple Indicator Cluster 
Surveys were used. Surveys were done between 2005 and 
2016, with over 80% of surveys done from 2010 onwards. 
We assumed no change in vaccine timing between the 
year of the survey and 2016. For 63 countries without 
surveys, the mean vaccine timing estimates from 
country surveys from the same WHO region and WHO 
mortality stratum15 were used. For surveys done before 
2016, to scale the study coverage to 2016 coverage values, 
the vaccine coverage by age distributions were scaled 
so that the 12-month coverage levels matched the 
2016 coverage estimates as reported by WHO/UNICEF 
Estimates of National Immunization Coverage.16 With 
this approach, the cumulative proportion of the 2016 
birth cohort that received each vaccine by week of age 
from birth until age 3 years was estimated.
12 hypothetical scenarios for timing of BCG vaccination 
were explored (table 1, figure), including various coverage 
levels with on-time or delayed vaccination assuming vac-
cine delivery at birth, 6 weeks, 6 months, or 9–12 months 
of age, including administration at the time of DTP1 or 
MCV1.
A meta-analysis of five randomised controlled trials 
estimated the relative risk of tuberculosis death in BCG-
vaccinated neonates versus unvaccinated neonates as 
0·34 (95% CI 0·12–0·92),3 corresponding to a vaccine 
efficacy of 66% (95% CI 8–88).
We reviewed published literature exploring BCG 
efficacy by age at vaccination on tuberculosis and all-cause 
mortality (appendix p4), identifying two clinical trials,17,18 
two observational studies,19,20 and one systematic review.5 
See Online for appendix
Point estimate (95% CI) Source
Population characteristics
Annual global BCG eligible birth cohort 129·1 million 9
Annual all-cause childhood deaths in birth cohort in children aged 0–4 years 6·8 million 11
Annual all-cause childhood deaths in birth cohort in children aged 5–9 years 643 000 11
Annual all-cause childhood deaths in birth cohort in children aged 10–14 years 560 000 11
HIV-negative paediatric male tuberculosis deaths in 2016 110 000 (75 000–151 000) 13
HIV-negative paediatric female tuberculosis deaths in 2016 91 000 (60 000–129 000) 13
Tuberculosis deaths in children younger than 5 years who had received tuberculosis treatment 
in 2015 (HIV negative)
2690 (1850–4180) 14
Tuberculosis deaths in children younger than 5 years who had not received tuberculosis 
treatment in 2015 (HIV negative)
161 000 (108 000–223 000) 14
Tuberculosis deaths in children aged 5–15 years who had received tuberculosis treatment in 
2015 (HIV negative)
2050 (1510–3100) 14
Tuberculosis deaths in children aged 5–15 years who had not received tuberculosis treatment in 
2015 (HIV negative)
31 500 (18 600–51 400) 14
Vaccine characteristics
Vaccine efficacy against tuberculosis death, % 66% (8–88) 3
Vaccine efficacy by age at administration Constant regardless of age of administration Assumption
Duration of protection 15 years 21
Waning of protection None Assumption
Table 2: Data inputs and model assumptions
For more on Demographic and 
Health Surveys see https://
dhsprogram.com/
For more on UNICEF Multiple 
Indicator Cluster Surveys see 
http://mics.unicef.org/ 
Articles
www.thelancet.com/lancetgh   Vol 7   December 2019 e1659
Together these studies are suggestive of non-specific 
effects of BCG, reducing mortality by more than would be 
expected through the effects on tuberculosis alone, and 
that the beneficial effects of BCG might decrease as age of 
vaccination increases. However, the systematic review 
found that the observational studies were at high risk20 or 
very high risk19 of bias, and the clinical trials were from 
low-birthweight infants from a single setting, so the 
results might not be generalisable to the global birth 
cohort. Overall, the systematic review found no conclusive 
evidence of an association between tuberculosis mortality 
and age of vaccination, and recommended further 
research in the area of non-specific effects.5 Therefore, in 
our model, BCG vaccine efficacy against tuberculosis 
death was assumed constant by age of administration, 
and non-specific effects were not included.
BCG was modelled as providing all-or-nothing 
protection, with vaccine efficacy as the proportion of 
vaccinated individuals completely protected against 
tuberculosis death. Infant BCG has a protective effect for 
at least 10 years following vaccination and evidence 
suggests that this effect might last up to 15 years.21 On 
this basis, BCG protection was assumed to last without 
waning for the 15-year model time period.
Paediatric tuberculosis is minimally infectious because 
pulmonary disease tends to be of low-bacillary load,22 
young children rarely produce a forceful enough cough 
to expel bacilli,22 and extrapulmonary disease is more 
common than in adults.23 Therefore, children rarely 
contribute to transmission, so it was assumed vaccination 
did not provide indirect effects, and the direct effects of 
vaccination were captured using a static mathematical 
model.
Uncertainty and sensitivity analyses
Oracle Crystal Ball was used to generate 100 000 iterations 
of the model, simultaneously sampling from each 
parameter distribution (table 1). We report median values 
and a 95% uncertainty range (UR) from these iterations. 
Where underlying parameter distributions were not 
stated, log-normal distributions were generated from each 
point estimate and 95% range using the 2·5%, 50%, and 
97·5% quantiles in the rriskDistributions package in the 
programme R, consistent with previous work.4 A summary 
of each parameter can be found in the appendix (p 5).
In the baseline scenario, a correlation coefficient of 
1 (perfect correlation) was assumed between the number 
of tuberculosis deaths in children who had received 
tuberculosis treatment and those who were untreated, 
and also between the numbers of tuberculosis deaths 
in children aged 0–4 years and 5–14 years.14 These 
assumptions were explored in a sensitivity analysis, 
which assumed no correlation (coefficient=0). A further 
sensitivity analysis explored the assumption of uniform 
risk of tuberculosis death in children aged 0–4 years, and 
considered the hypothetical situation where 100% of 
deaths in this age group occurred in children aged 
0–2 years. In each case the model was re-run an additional 
100 000 times.
Role of the funding source
WHO provided financial support to the London Schoold 
of Hygiene & Tropical Medicine TB Modelling Group to 
conduct this work, contributed to the development of the 
research question, and reviewed manuscript drafts. 
WHO had no role in data collection, data analysis, or data 
interpretation, and writing of this report. The 
corresponding author had full access to the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
In 152 LMICs, we estimate that 37% of the 2016 birth 
cohort received BCG in the first week of life, and 
67% coverage was achieved by 6 weeks of age. BCG 
coverage was estimated to be 90% at 1 year of age and 
92% at 3 years of age (table 3). An estimated 7·7% of the 
birth cohort received DTP1 before the recommended 
6 weeks of age, with 50% coverage achieved between 
9 and 10 weeks of age. Coverage at 1 year was estimated at 
89% and at 3 years was estimated at 94%. Coverage of 
MCV1 reached 50% between 43 and 44 weeks, with 
67% coverage and 93% coverage at 1 year and 3 years of 
age, respectively (table 3).
The modelled number of HIV-negative tuberculosis 
deaths in the baseline scenario (scenario A) for the 
2016 birth cohort over the first 15 years of life was 
200 830 (95% UR 141 457–285 169), consistent with 
WHO estimates.13 Achieving 92% BCG coverage at 
birth (scenario B), rather than at the current 3 years of 
WHO recommended 
age of first dose
Age by which 50% coverage of 
the 2016 birth cohort is 
achieved
Estimated coverage of 
the 2016 birth cohort 
at 1 year of age
Estimated coverage of 
the 2016 birth cohort 
at 3 years of age
Comments
BCG At birth or as soon as 
possible after birth
Between 2 and 3 weeks of age 90% 92% An estimated 37% of the 2016 birth cohort received BCG in the first week 
of life
DTP1 6 weeks Between 9 and 10 weeks of age 89% 94% An estimated 7·7% of the 2016 birth cohort received DTP1 before 6 weeks 
of age
MCV1 9 or 12 months Between 43 and 44 weeks of age 67% 93% An estimated 9·6% of the 2016 birth cohort received MCV1 before 
9 months of age
Table 3: Vaccine coverage by age distributions for the 2016 birth cohort across 152 low-income and middle-income countries for BCG, the first dose of diphtheria–tetanus–pertussis 
vaccine (DTP1), and the first dose of measles-containing vaccine (MCV1)
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age, was estimated to reduce tuberculosis deaths by 
2·8% (UR 0·1–7·0) or 5449 fewer tuber culosis deaths 
(UR 218–15 071) per global birth cohort over the first 
15 years of life (table 4). 100% BCG coverage at birth 
(scenario C) would reduce tuberculosis mortality by 
16·5% (0·7–41·9), or 32 758 fewer deaths (1292–90 412).
In contrast, in all the other modelled scenarios, 
later BCG vaccination was associated with increased 
tuberculosis mortality, even if it was associated with 
improved BCG coverage (table 4). If BCG was globally 
administered at around 6 weeks of age, it was estimated 
that 92% instantaneous coverage (scenario D) would 
result in increased mortality of 0·1% (0–0·3), compared 
with the current situation, while delaying the baseline 
distribution of age at BCG by 6 weeks (scenario E) would 
increase mortality by 2·9% (0·1–7·3). If BCG was 
delivered globally at the time of DTP1, tuberculosis 
mortality would increase by 2·8% (0·1–7·1), equivalent 
to 5556 more deaths (220–15 224) if BCG coverage 
remained at 92% (scenario F1), or by 0·2% (0–0·4), 
equivalent to 332 more deaths (11–964) if BCG coverage 
increased to 94% to match DTP1 coverage (scenario F2). 
Achieving 92% instantaneous coverage at 6 months 
(scenario G) was estimated to increase tuberculosis 
mortality by 9·8% (0·4–24·7), while shifting the baseline 
distribution of age at BCG by 6 months (scenario H) was 
estimated to result in an increase of 12·5% (0·5–31·6; 
table 4). If BCG was to be administered at the time of 
MCV1 at 9–12 months of age, mortality would increase 
by an estimated 19·9% (0·8–50·2) if BCG coverage 
remained at 92% (scenario I1), or by 18·4% (0·7–46·3) if 
BCG coverage increased to match MCV1 coverage of 
93% (scenario I2). Instantaneous 92% coverage at 
12 months (scenario J) would increase mortality by an 
estimated 22·2% (0·9–56·1), while delaying the current 
baseline distribution by 12 months (scenario K) was 
estimated to increase mortality by 25·0% (1·0–63·1).
Exploring the assumptions of correlation between 
number of tuberculosis deaths in children aged 0–4 years 
and 5–14 years, and correlation between number of 
treated versus untreated deaths, had a negligible effect 
on mortality estimates (appendix p 6). When all tuber-
culosis deaths in children younger than 5 years were 
modelled to occur between the ages of 0–2 years, 
100% BCG vaccination at birth was estimated to reduce 
tuberculosis deaths by 19·6% (0·8–47·2), while all 
scenarios of later vaccination resulted in even greater 
increases in tuberculosis deaths compared with the 
main analysis (appendix p 6).
Discussion
In 152 LMICs with a policy of neonatal BCG vaccination, 
we estimated that 37%, 67%, and 90% of the 2016 birth 
cohort received BCG by 1 week, 6 weeks, and 1 year 
of age, respectively. Coverage at 3 years of age was 
estimated to be 92%. By eliminating delays in BCG 
administration and achieving 92% BCG coverage at 
birth, rather than as currently at 3 years of age, we 
estimated a reduction in tuberculosis deaths in the 
global birth cohort over the first 15 years of life of 
Scenario description Total number of childhood 
tuberculosis deaths per birth 
cohort in the first 15 years of 
life (95% UR)
Change in number of 
tuberculosis deaths 
compared with 
Scenario A (95% UR)
Median percentage change 
in number of tuberculosis 
deaths compared with 
scenario A (95% UR) 
A Baseline BCG vaccination coverage by age distribution (92% final coverage) 200 830 (141 457 to 285 169) ·· ··
B 92% immediate coverage at birth 194 857 (136 943 to 277 490) –5499 (–15 071 to –218) –2·8% (–7·0 to –0·1)
C 100% immediate coverage at birth 165 174 (101 880 to 249 423) –32 758 (–90 412 to –1292) –16·5% (–41·9 to –0·7)
D 0% coverage until 6 weeks of age, then 92% immediate coverage at 6 weeks 201 103 (141 645 to 285 642) 264 (10 to 724) 0·1% (0 to 0·3)
E 0% coverage until 6 weeks of age, then 92% final coverage delaying the baseline BCG 
coverage distribution by 6 weeks
207 013 (145 717 to 294 531) 5757 (228 to 15 775) 2·9% (0·1 to 7·3)
F1 BCG global delivery at the time of DTP1, using DTP1 coverage by age distribution (capped 
when coverage reached 92%)
206 805 (145 590 to 294 274) 5556 (220 to 15 224) 2·8% (0·1 to 7·1)
F2 BCG global delivery at the time of DTP1, using 2015 DTP1 coverage by age distribution 
(final coverage of 94%)
201 165 (141 703 to 285 809) 332 (11 to 964) 0·2% (0 to 0·4)
G 0% coverage until 6 months of age then 92% immediate coverage at 6 months 221 584 (153 809 to 319 965) 19 426 (769 to 53 226) 9·8% (0·4 to 24·7)
H 0% coverage until 6 months of age, then 92% final coverage delaying the baseline BCG 
coverage distribution by 6 months
227 281 (156 543 to 331 633) 24 896 (986 to 68 213) 12·5% (0·5 to 31·6)
I1 BCG global delivery at the time of MCV1, using 2015 MCV1 coverage by age distribution 
(capped when coverage reached 92%)
242 124 (162 805 to 365 403) 39 553 (1567 to 108 364) 19·9% (0·8 to 50·2)
I2 BCG global delivery at the time of MCV1, using 2015 MCV1 coverage by age distribution 
(final coverage of 93%)
239 091 (161 666 to 358 146) 36 506 (1445 to 99 882) 18·4% (0·7 to 46·3)
J 0% coverage until 12 months of age, then 92% immediate coverage at 12 months 246 749 (164 570 to 376 504) 44 219 (1751 to 121 142) 22·2% (0·9 to 56·1)
K 0% coverage until 12 months of age, then 92% final coverage delaying baseline BCG 
coverage distribution by 12 months
252 217 (166 424 to 389 637) 49 660 (967 to 136 043) 25·0% (1·0 to 63·1)
UR=uncertainty range. DTP1=first diphtheria–tetanus–pertussis vaccine dose. MCV1=first measles-containing vaccine dose.
Table 4: Estimated tuberculosis mortality per birth cohort in the first 15 years of life according to different BCG vaccination scenarios
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5449 deaths (UR 218–15 071), equivalent to 2·8% 
(UR 0·1–7·0). Furthermore, achieving 100% BCG cov-
erage at birth, in line with WHO recommendations, 
would reduce tuberculosis deaths by 32 758 (1292–90 412) 
or 16% (0·7–42). Later administration would increase 
tuberculosis deaths in all the modelled scenarios. For 
example, global administration of BCG at the time of 
DTP1, recommended at 6 weeks, would increase tuber-
culosis deaths by 0·2% (0–0·4) even if BCG coverage 
reached DTP1 coverage levels (94% by age 3 years). The 
longstanding WHO recommendation for BCG at birth 
has, therefore, likely averted a substantial number of 
childhood tuberculosis deaths that would have occurred 
had BCG been recommended later in the vaccination 
schedule. Our analysis supports the updated WHO 
position paper on BCG vaccines, which recommends 
that in countries with a high incidence of tuberculosis, 
BCG should be given to all healthy neonates at birth or 
at the earliest opportunity thereafter.8
Childhood tuberculosis remains a substantial global 
public health problem, with almost 250 000 deaths and 
more than 1 million new cases in 2017.24 The international 
tuberculosis community has endorsed an ambitious 
goal of zero childhood tuberculosis deaths.25 If this 
target is to be achieved, vaccination will undoubtedly 
play a crucial role. Although 100% BCG coverage at 
birth is unlikely to be achieved, our analyses have 
shown the importance of both eliminating delays and 
increasing coverage, and the reductions in childhood 
tuberculosis mortality that could be achieved in ideal 
circumstances. Although new tuberculosis vaccines are 
in development, BCG remains the only tuberculosis 
vaccine currently available on the global market, and 
until new vaccines are widely avail able, efforts to 
improve the timing and coverage of BCG should be 
emphasised.
There are several reasons why BCG delivery might be 
delayed. Children born at home might have infrequent 
contact with health workers, many countries operate a 
policy of delayed vaccination for low-birthweight children, 
and some countries have a policy of not opening multidose 
BCG vials until a sufficient number of children are present 
to minimise vaccine wastage (restricted vial opening 
policies).26 In Guinea-Bissau, restricted vial opening poli-
cies have resulted in mothers being asked to return on 
another occasion for their children to receive the vaccine, 
thereby leading to further delays.27 In this setting, when 
BCG was provided regardless of the number of children 
present, delays were substantially reduced.27 Where clinics 
vaccinate seven or fewer children daily, production of 
BCG in 10-dose vials has been estimated to be cost-
effective.28 Therefore, both policy recommendation and 
reduced vial size could help encourage vial opening, 
potentially leading to reduced delays and, therefore, 
preventable childhood mortality.
Although our research has focused on the reduction of 
tuberculosis mortality, there is an additional potential 
reduction in all-cause mortality from administering 
BCG at birth. However, because the evidence base for 
non-specific effects of BCG is still emerging and currently 
inconclusive,5 we have not incorporated this outcome into 
our model. For example, studies reporting non-specific 
effects have sometimes produced seemingly conflicting 
results. Although it has been reported that simultaneous 
administration of BCG and DTP1 at 6 weeks of age might 
be associated with reduced all-cause mortality,29 it has also 
been reported that BCG at birth reduces all-cause mortality 
compared with delayed vaccination.17 The potential 
additional effect of BCG on all-cause mortality is an 
interesting research question, and could be incorporated 
into future models once improved data from ongoing 
research become available.
This study has several strengths. It is the first study to 
explore the potential effect of age of BCG vaccination on 
global paediatric tuberculosis mortality. The scenarios 
exploring delivery of BCG vaccination at birth provide 
evidence of the benefits of on-time vaccination and a 
theoretical benchmark for the potential reduction in 
tuberculosis deaths. Secondly, the accuracy of our model 
estimates was strengthened by use of age-specific vaccine 
coverage data based on household surveys, rather than 
using country-level final coverage estimates, which do 
not take vaccine delays into account. As a result, 
theoretical scenarios whereby global administration of 
BCG would be deferred, to coincide with DTP1 or MCV1, 
account for the fact that vaccine administration is often 
distributed around, and mainly after, the recommended 
age, therefore providing more realistic estimates than 
simply assuming that vaccination takes place only at 
the recommended age. Finally, methods for estimating 
the burden of childhood tuberculosis at a global and 
individual country level are continuously evolving. 
Although this model was developed using 2016 data, it is 
set up so that any new global estimates of tuberculosis 
mortality could be incorporated to produce updated 
estimates or could be adapted to a specific country with 
available data.
This study has several limitations. First, we have used 
the best available estimate of age-specific tuberculosis 
mortality,14 but data to inform this parameter were limited 
to 0–4 years and 5–14 years age groups. Children younger 
than 2 years are most at risk of tuberculosis death;8 
therefore by assuming uniform risk between ages 
0–4 years, our model might have underestimated the true 
mortality benefit of delivering BCG on time at birth, and 
the consequences of delivering BCG later in the infant 
schedule. Although a sensitivity analysis modelled a 
scenario in which all tuberculosis deaths in children 
younger than 5 years occurred between the ages of 0 and 
2 years, more precise data on how tuberculosis deaths are 
stratified by age could improve future model estimates.
Second, data on BCG vaccine efficacy were limited. The 
parameter of vaccine efficacy against tuberculosis death3 
had large confidence intervals, and so the URs presented 
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around each modelled estimate are wide. However, these 
ranges show the values that might be achieved at different 
levels of true vaccine efficacy. Therefore, overlapping URs 
between scenarios should not be interpreted as a lack of 
difference between scenarios, because regardless of 
vaccine efficacy, the relative difference between scenarios 
would remain consistent. Improved estimates of vaccine 
efficacy against tuberculosis death would result in 
narrower URs. Additionally, due to absence of conclusive 
evidence, our model assumed constant vaccine efficacy 
against tuberculosis death regardless of age of admin-
istration. This assumption might not be true because 
evidence suggests that BCG is more efficacious in 
individuals not previously sensitised to Mycobacterium 
tuberculosis,2 and that potential non-specific effects might 
decrease with age.17,19 However, declining BCG vaccine 
efficacy with age would be anticipated to increase 
estimates of tuberculosis mortality with later BCG 
administration, and would further strengthen the case for 
the birth dose.
Third, by assuming that tuberculosis deaths in HIV-
infected infants are not vaccine-preventable, we have not 
included the potential effect of BCG vaccination on 
tuberculosis mortality in this cohort of individuals. 
BCG is contraindicated in neonates with known HIV 
infection, unless on antiviral treatment and immu-
nologically stable, because of the increased risk of 
disseminated BCG disease. Yet, HIV-infected neonates 
might receive BCG if their HIV status is unknown at 
birth, the risks and benefits of which have not been 
accounted for in this research. In addition, coverage in 
the scenario of BCG vaccination alongside DTP1 might 
have been overestimated, because HIV status is more 
likely to be known by this stage, although the number of 
infants affected is likely to be small.
Finally, because paediatric tuberculosis cases are mini-
mally infectious, we used static modelling. As such, our 
model does not account for any potential further reduction 
in cases due to decreased disease transmissibility or 
indirect vaccine effects, although any potential effect is 
likely to be small.
In future work, this model could be strengthened by 
improved information on vaccine efficacy by age and 
more stratified estimates of age-specific tuberculosis 
mortality. Whether smaller multidose vials or unrestricted 
vial-opening policies would lead to improved coverage 
and reduced delays should also be investigated.
In conclusion, BCG remains a cornerstone of child-
hood tuberculosis prevention policy, but delays in its 
administration still exist in many settings. Eliminating 
these delays and increasing coverage at birth would 
lead to a substantial reduction in global paediatric 
tuberculosis mortality. Modelled scenarios whereby BCG 
is administered later in the infant schedule were all 
estimated to increase tuberculosis deaths. The WHO 
recommendation for BCG at birth should be maintained 
and emphasised.
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